Explore
Validate
Learn307402
antibody from BioLegend
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 307402 - Provider product page
- Provider
- BioLegend
- Proper citation
- BioLegend Cat#307402, RRID:AB_314674
- Product name
- Purified anti-human CD262 (DR5, TRAIL-R2)
- Antibody type
- Monoclonal
- Antigen
- Extracellular domain of DR5-human IgG1 Fc fusion protein
- Description
- DR5 is 55 kD member 10B of the TNF receptor superfamily (TNFRSF10B), also known as TRAIL-R2, TRICK2, KILLER, and CD262. It binds the cytotoxic ligand TRAIL and induces apoptosis. The DR5 receptor is broadly expressed on a variety of normal tissues and many tumors. DR5 expression has been reported to be upregulated in human cells by interferon-α, 2-methoxyestradiol, and paclitaxel, and downregulated by adenoviral E3 proteins.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 0.5 mg/ml
- Storage
- The antibody solution should be stored undiluted at 4°C.
Submitted references Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R
Cancer research 2006 Jul 15;66(14):7317-25
Cancer research 2006 Jul 15;66(14):7317-25
No comments: Submit comment
Supportive validation
- Submitted by
- BioLegend (provider)
- Main image
- Experimental details
- Human peripheral blood lymphocytes stained with purified DJR2-4, followed by biotinylated anti-mouse IgG and Sav-PE
- Conjugate
- Unconjugated
